CSL Moves Up International Biotech Market Capitalisation Rankings Driven By R&D Investment

January 20th, 2020 blood cells

A report in the Australian Financial Review has highlighted the remarkable performance of CSL over recent years, largely due to the company’s investment in R&D Activity.
The report has highlighted:
  • CSL’s share price has increased more than 50% during 2019, which is rare for a company of such size and maturity;
  • If CSL maintains their current trajectory, it may shortly overtake Commonwealth Bank of Australia as the 2nd most valuable stock on the ASX by market capitalisation;
  • CSL is now ranked as the third most valuable biotech internationally by market capitalisation (behind only Amgen and Novo Nordisk) and has overtaken companies such as Biogen and Allegan;
  • CSL spends around 10% of sales on R&D Activity investment, and the current year R&D budget is $1.4B. This includes R&D activity in both Australia and internationally.
CSL has also been vocal in urging the government to maintain stable R&D Tax Incentives as a means of giving business confidence to invest in long-term Australian R&D projects, rather than utilising overseas R&D Facilities. Given CSL’s international success, their tax policy views should be held in high regard as the Australian Parliament considers the government’s proposed reforms to the R&D Tax Incentive in the coming months. Proposed reforms include significant changes such as the “Intensity Threshold,” which has been widely criticised as overly complex and reducing the incentive to conduct R&D Activity.
Source: Australian Financial Review

Post a Comment

(*) indicates required field.

Categories

Archives

Swanson Reed - Specialist R&D Tax Advisors
Swanson Reed - Specialist R&D Tax Advisors
39 Google reviews
Daniel McGregor
Daniel McGregor
2022-08-11
I have been using Swanson Reed for my clients for more than a decade. Having a specialist firm that can provide practical and commercial advice that produces real outcomes is very important and we have received great feedback from our clients. Highly recommended.
John
John
2022-06-15
Damian and the rest of the team at Swanson Reed have been supporting us for several years. We always appreciate their insights, expertise, and efforts.
Rueben Rajasingam
Rueben Rajasingam
2022-06-06
Experienced responsive Team. They have been a great help to me and my company navigate the R&D tax claim process and have provided invaluable advice.
Enrique Esquivel
Enrique Esquivel
2022-06-06
Damian and the team at Swanson Reed have been extremely helpfully and professional during all of our consultations. Highly recommended.
Jess at Y&C
Jess at Y&C
2022-06-03
Anatole Kononewsky
Anatole Kononewsky
2022-06-02
The Swanson Reed team have provided our company with exceptional professional advice and assistance for all of our R&D claims for many years - have always achieved great results with excellent value for their services.
Payam Toloo
Payam Toloo
2022-06-02
Damian Smyth and his team are very helpful, supportive and experts in their field of R&D Tax claims. I'm always happy with the work they do and been a customer of their for over 5 years.
Melissa Doddy
Melissa Doddy
2022-05-31
The Team at Swanson Reed are very experienced R&D Tax Advisors and gave us ongoing support with all of our R&D Claims, the consultants ensured we were always working with current legislative guidelines, gave us assistance with compiling technical and government documentation and went out their way to ensure they were with us for the entire process from beginning to end. Highly recommended to anyone who needs assistance with working through what can at times be a daunting process.
Gary Watson
Gary Watson
2022-05-31
We can highly recommend Swanson and Reed as an R & D accountant. We have worked with them for several years now as they make our R & D claim so easy and communicate quickly with both us and our accountant.
Rob van den Bergh
Rob van den Bergh
2022-05-31
Always professional.